Introduction
============

Cancer is becoming one of the main causes of death and is a hard challenge to the world [@B1]. Early diagnosis and prognosis prediction are helpful for clinical treatment of cancers [@B2], but traditional detection methods such as biopsy and imaging techniques still have their limitations. Therefore, it is urgently needed to excavate new molecular signatures for the early and precise prognosis prediction of cancers.

Both gene copy number variations and mRNA expression levels (or protein expression levels) in cancer cells could be used as signatures for prognosis and response to therapies. For example, *HER2* amplification was an efficient predictor of overall survival in breast cancer patients [@B3]. Amplification, genetic rearrangement and overexpression of cell cycle cyclins genes had been documented in almost all human cancer types and contributed to development and progression of cancers [@B4]. Cyclin E1, encoded by the *CCNE1*, drives the transition from G1 to S phase by binding and activation of cyclin dependent kinase 2 (CDK2), resulting in the initiation of DNA synthesis [@B5]. Up to now, an increasing number of studies had reported the relations between *CCNE1* and prognosis in diverse cancers, but still generated discrepant conclusions. For instance, overexpression and copy number amplification of *CCNE1* were related to poor survival in some kinds of malignant tumors such as bladder cancer [@B6], breast cancer [@B7], ovarian cancer \[8\]and so on, while some opposite results existed [@B9], [@B10]. Therefore, the prognostic value of *CCNE1* in cancer patients remained uncertain.

It\'s worth noting that, in some literatures, Cyclin E1 and Cyclin E2 (encoded by *CCNE2*) were collectively referred to as Cyclin E [@B11]-[@B13], while Cyclin E1 was formerly called as Cyclin E in some studies [@B14]. Furthermore, Cyclin E2 was also found to be associated with prognosis in several kinds of cancer [@B15], [@B16]. Therefore, research results derived from articles about Cyclin E without definite indication of Cyclin E1 (or *CCNE1*) in the full text were not explicit, because we couldn\'t determine whether these conclusions were the separate effect of Cyclin E1 or the combined effect of Cyclin E1 and Cyclin E2. So in this study, we conducted a rigorous systematic review and meta-analysis for the prognostic values of *CCNE1* amplification and overexpression rather than Cyclin E.

Materials and Methods
=====================

Literature search
-----------------

Comprehensive literature search of PubMed, Cochrane library, Embase, CNKI database and WanFang database was performed for articles published prior to February 15, 2018 by using Medical Subject Headings (MeSH) combined with keywords as follows: "cyclin E1, human", "*CCNE1*", "Cyclin E1", "CCNE", "Cyclin Es", "Cyclin Et", "G1/S-Specific Cyclin-E1", "Prognosis", "Survival", "Prognoses", "Factor, Prognostic", "Prognostic Factor", "Carcinoma", "Neoplasms", "Neoplasia", "Neoplasm", "Tumor", "Cancer", "Malignancy", "Benign Neoplasm", "Neoplasm, Benign", "Malignant Epithelial Neoplasm", "Epithelioma", "Carcinomatosis". Additionally, we conducted the manual search of the references in all included articles to identify potential missing studies that were not found during the preliminary literature searches. Inclusion criteria for the included studies: (1) all articles should be published either in English or Chinese language in the form of full article; (2) observational studies (case-control or cohort studies) that investigated patients with any type of cancer; (3) articles investigating the correlations between *CCNE1* expression levels (protein expression level or mRNA expression level) and the prognosis in cancer patients or the correlations of *CCNE1* amplification and the prognosis in cancer patients; (4) Hazard ratio (HR) and 95% confidence interval (95% CI) of survival assessment parameters were reported directly, or there was sufficient original data for estimating them in article; (5) when the patient cohorts overlapped among different publications, only the largest or the most recent one was included. Exclusion criteria were as follow: (1) studies without usable or sufficient data; (2) case reports, reviews, letters, comments, conference abstracts and expert opinions; (3) article about Cyclin E in which there was no definite indication of Cyclin E1 (*CCNE1*); (4) researches about a set of genes rather than *CCNE1* alone; (5) results from overlapping patients cohorts; (6) articles based on external datasets. Screening of eligible studies was independently performed by four investigators (HY.Z, JL.W, LS.L, HL.Y), disagreements were resolved by consensus.

Data extraction and quality assessment
--------------------------------------

Four investigators (HY.Z, JL.W, LS.L, and HL.Y) independently extracted the available data from all included studies. The extracted data was crosschecked and any discrepancy was resolved by discussion. The following information was extracted from each included study: first author name, publication year, study design, cancer type, inclusion period, case and control numbers, research country, region, method for detecting *CCNE1* amplification, method for detecting *CCNE1* expression level, cut off value, research center, duration of follow-up, HR and 95% CI. If the article only reported Kaplan-Meier curve (K-M curve) without providing HR and 95% CI directly, appropriate data was extracted from the survival curves by using Engauge Digitizer 4.1 software and the logHR and selogHR were calculated according to Tierney et al [@B17]. This method was conducted by three investigators to reduce imprecision. For studies that reported both the univariate and multivariate analysis results, the latter was extracted. Survival assessment parameters with HR and 95% CI available in these included studies were selected in our research, including overall survival (OS), progression free survival (PFS), cancer specific survival (CSS), recurrence free survival (RFS) and distant metastasis free survival (DMFS). The Newcastle-Ottawa Scale (NOS) [@B18] was used to assess the quality of each included study. The NOS score ranged from 0 to 9, and a study with score \>7 was considered as high quality. Three investigators (HY.Z, JL.W, LS.L) independently scored each study, any discrepancy was resolved by discussion.

Statistical Analysis
--------------------

We used HR with corresponding 95% CI to calculate pooled data. By convention, HR\>1 indicated poor prognosis for the *CCNE1* amplification or overexpression group. The heterogeneity among studies was determined by Q test and I^2^ value [@B19]. When *p*\<0.05 for the Q test or I^2^\>50%, heterogeneity was supposed to be significant, and then the random effect model was applied. On the contrary, fixed effect model was employed (*p*≥0.05 or I^2^≤50%). Publication bias was evaluated by Egger\'s test [@B20]. And when the number of included studies was \<10, publication bias analysis was not conducted. Subgroup analysis was performed to find out factors contributing to heterogeneity. One-way sensitivity analysis was performed to assess the stability of results, but when the number of included studies was \<3, it was not conducted. *P* values in all analyses were two sides, and *p*\<0.05 was considered statistically significant. All statistical analyses in this meta-analysis were conducted with STATA 12.0 (Stata Corporation, College Station, TX, USA).

Results
=======

Identification of relevant studies
----------------------------------

By applying the described searching strategy, we initially collected 528 publications. After exclusion of duplicates and irrelevant studies by reviewing the titles and abstracts, 47 articles remained for further evaluation. We reviewed all of the 47 publications by reading full manuscripts, and excluded 27 articles as follows: 7 [@B21]-[@B27] articles lacking sufficient information, 6 [@B28]-[@B33] articles based on external datasets, 1 [@B34] article with overlapping data, 3 [@B35]-[@B37] articles reporting gene sets including *CCNE1* rather than *CCNE1* as a single gene signature for prognosis and 10 [@B38]-[@B47] articles about Cyclin E in which there were no explicit indication of *CCNE1*. Finally, 20 studies were qualified and included in our research. Among them, 1 article only exploring the predictive roles of*CCNE1* copy number amplification in cancer prognosis [@B48], 14 articles were only about *CCNE1* expression levels (on mRNA or protein expression level) [@B6], [@B7], [@B10], [@B49]-[@B59], and 5 articles examined both *CCNE1* amplification and expression levels [@B8], [@B9], [@B60]-[@B62]. The detailed procedure of literature retrieval is revealed in Figure [1](#F1){ref-type="fig"}. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram to design, analyze, and report this meta-analysis [@B63].

Study characteristics
---------------------

The main characteristics of the included 6 studies that explored the prognostic value of*CCNE1* amplification in cancers are presented in Table [1A](#T1A){ref-type="table"}. 1120 patients were enrolled in these researches totally, and the cohort sizes ranged from 83 to 489 cases with the mean of 186. There were 4 articles on ovarian cancer, 1 literature about endometrial carcinomas and 1 research on breast cancer. For detecting the amplification of *CCNE1*, fluorescence in situ hybridization (FISH) was applied in 3 studies, copy number polymerase chain reaction (PCR) in 1 study, microarray in 1 study and chromogenic in situ hybridization (CISH) in 1 study. *CCNE1* amplification proportion varied from 8.33% to 25%, with the mean percentage of 16.54%. HR and 95% CI were directly reported in 5 studies and extracted from K-M curves in 1 study. All studies assessed *CCNE1* amplification in tumor tissue.

The main characteristics of the 19 included studies that researched on the predictive roles of *CCNE1* expression level in cancers prognosis are shown in Table [1B](#T1B){ref-type="table"}. The total number of patients included in these articles was 4592, and the sample size ranged from 60 to 857 with the mean value of 242. There were 8 articles on breast cancer, 5 literatures about ovarian cancer, 3 researches on bladder cancer, 1 study about endometrial carcinomas, 1 article about esophageal adenocarcinoma and 1 research on upper tract urothelial carcinoma. For detecting expression levels of *CCNE1*, immunochemistry (IHC) was applied to evaluate CCNE1 protein expression level in 12 studies, real-time quantitative polymerase chain reaction (RT-qPCR) was performed to detect *CCNE1* mRNA expression level in 6 studies, and microarray was conducted to detect *CCNE1* mRNA expression level in 1 study. 3 articles treated *CCNE1* expression level as continuous type variable, so there were no specific cut-off values in them [@B9], [@B56], [@B57]. In the remaining 16 articles, *CCNE1* expression level was all classified as high and low group, but the cut-off definitions were various. HR and 95% CI were directly reported in 15 studies and extracted from K-M curves in 4 studies. All studies assessed *CCNE1* expression levels in tumor tissue.

As shown in Table [S1](#SM0){ref-type="supplementary-material"}, global quality assessment scores of the 20 included studies in this study were generally high with 14 (70%) articles being more than 7 points, ranged from 6 to 8.

Survival analysis for *CCNE1* amplification carriers with cancers
-----------------------------------------------------------------

**OS analysis**: 5 studies with totally 935 patients investigated the association between *CCNE1* amplification and OS. A random effect model was used to estimate the pooled HR and 95% CI, due to a significant heterogeneity among these 5 studies (I^2^=75%, *p*=0.003). As shown in Figure [2](#F2){ref-type="fig"}A, the results demonstrated that *CCNE1* amplification carriers were associated with worse OS than non-carriers, with a pooled HR of 1.59 (95% CI: 1.05-2.40, *p*=0.027). The results of subgroup analyses were presented in Table [S2](#SM0){ref-type="supplementary-material"}A. It revealed that analysis method, detection method, region, and research center might contribute to the heterogeneity. It was noteworthy that, of these 5 included studies, 4 studies focused on ovarian cancer, but *CCNE1* amplification had no significant relationship with OS in ovarian cancer patients (HR=1.46, 95% CI: 0.98-2.18, *p*=0.064). In studies adopting multivariate analysis rather than univariate analysis, *CCNE1* amplification carriers had statistically significantly worse OS (multivariate analysis: HR=3.45, 95% CI: 1.76-6.77, *p*\<0.001; univariate analysis: HR=1.22, 95% CI: 0.90-1.65, *p*=0.193).

**PFS analysis**: 3 studies of 363 patients assessed the predictive value of *CCNE1* amplification for PFS. Significant heterogeneity was found across these included studies (I^2^=62.3%, *p*=0.07), so the pooled HR was calculated based upon a random effects model. Meta-analysis results demonstrated no significant association between *CCNE1* amplification and PFS (HR=1.49, 95% CI: 0.83-2.67, *p*=0.177) (Figure [2](#F2){ref-type="fig"}B). As shown in Table [S2](#SM0){ref-type="supplementary-material"}B, the results of subgroup analyses revealed that analysis method, detection method, region, and research center might contribute to the heterogeneity. We also found that there was no statistical difference in PFS between CCNE1 amplification carriers and non-carriers, regardless of tumor type or study quality. However, it was worth noting that, in studies adopting multivariate analysis, *CCNE1* amplification carriers showed significantly worse PFS (HR=2.20, 95% CI: 1.20-4.04, *p*=0.011).

**RFS analysis**: only 1 study enrolling 185 patients reported the predictive values of *CCNE1* amplification for RFS in breast cancer, with the HR of 0.982 (95% CI: 0.2376-4.059, *p*=0.9801), indicating no significant relationship between them in breast cancer patients.

Survival analysis for *CCNE1* overexpression carriers with cancers
------------------------------------------------------------------

**OS analysis:** 10 studies with 1562 patients researched on the association between *CCNE1* expression levels and OS. The random effect model was applied to estimate the pooled HR with corresponding 95% CI. As shown in Figure [3](#F3){ref-type="fig"}A, there was significant heterogeneity among these included studies (I^2^=78.5%, *p*\<0.001), meta-analysis results demonstrated that there was significant difference in OS between high *CCNE1* expression level group and low CCNE1 expression level group. *CCNE1* overexpression carriers were associated with worse OS than non-carriers, with a pooled HR of 1.52 (95% CI: 1.05-2.20, *p*=0.027). Subgroup analyses revealed that *CCNE1* overexpression carriers had statistically significantly shorter OS compared to non-carriers in studies as followed: on breast cancer or upper tract urothelial carcinoma; detecting by IHC method; about protein expression level; conducted in Asia or mixed region; with HR and 95% CI reported directly or with high quality. Noteworthily, of these 10 included studies, 5 studies were about ovarian cancer, but *CCNE1* overexpression had no significant relationship with OS in ovarian cancer patients (HR=1.28, 95% CI: 0.81-2.03, *p*=0.283) (Table [S3](#SM0){ref-type="supplementary-material"}A).

**PFS analysis:** Since there was no significant heterogeneity across 5 included studies involving 666 patients (I^2^=41%, *p*=0.148), the fixed effect model was applied. Compared with low *CCNE1* expression group, *CCNE1* overexpression group had a significantly worse PFS (HR=1.20, 95% CI: 1.07-1.34, *p*=0.001) (Figure [3](#F3){ref-type="fig"}B). The results of subgroup analyses were presented in Table [S3](#SM0){ref-type="supplementary-material"}B. It revealed that analysis method might contribute to the heterogeneity. In studies adopting multivariate analysis, *CCNE1* overexpression predicted statistically significantly poorer PFS (multivariate analysis: HR=1.29, 95% CI: 1.13-1.47, *p*\<0.001; univariate analysis: HR=1.01, 95% CI: 0.82-1.24, *p*=0.958). However, of these 5 included studies, 3 studies were about ovarian cancer, but *CCNE1* overexpression didn\'t show prognostic prediction ability for PFS in ovarian cancer patients (HR=1.14, 95% CI: 0.97-1.34, *p*=0.109).

**RFS analysis**: 5 studies encompassing 1140 patients investigated the predictive values of *CCNE1* overexpression for RFS in cancers. As the result of meta-analysis exhibited obvious heterogeneity (I^2^=83.0%, *p*\<0.001), the random effect model was used. As shown in Figure [3](#F3){ref-type="fig"}C, meta-analysis results revealed no association between *CCNE1* overexpression and RFS, with a pooled HR of 1.68 (95% CI: 0.81-3.50, *p*=0.164). Subgroup analyses results showed that the source of HR might contribute to the heterogeneity. It was notable that, of these 5 included studies, there were 4 studies with HR and 95% CI from literatures reported directly, and *CCNE1* overexpression were associated with poorer RFS (HR=2.1, 95% CI: 1.31-3.36, *p*=0.002) in them (Table [S3](#SM0){ref-type="supplementary-material"}C).

**CSS analysis**: 4 studies enrolling 881 patients assessed the association between *CCNE1* expression levels and CSS. The *p* and I^2^ values of heterogeneity test were \<0.001 and 90.4% respectively. After using random effect model, the pooled HR was 1.54 (95% CI: 0.74-3.18, *p*=0.246), indicating CCNE1 expression level didn\'t have significant correlation with CSS in cancer patients (Figure [3](#F3){ref-type="fig"}D). The results of subgroup analyses were presented in Table [S3](#SM0){ref-type="supplementary-material"}D.

**DMFS analysis**: A random effect model was used to estimate the pooled HR with corresponding 95% CI, due to a significant heterogeneity across 3 included studies with 1678 patients (I^2^=86.6%, *p*=0.001). As shown in Figure [3](#F3){ref-type="fig"}E, overexpression of *CCNE1* might predict poorer DMFS in cancer patients, with a pooled HR of 1.62 (95% CI: 1.09-2.40, *p*=0.017). The results of subgroup analyses were presented in Table [S3](#SM0){ref-type="supplementary-material"}E.

Sensitivity analysis
--------------------

For the analysis groups about prognostic values of *CCNE1* amplification on OS and PFS or about prognostic values of *CCNE1* overexpression on OS, PFS, CSS, RFS and DMFS in cancer patients, sensitivity analyses were all performed by removing each study in turn from the pooled analysis. As showed in Figure [4](#F4){ref-type="fig"}-[5](#F5){ref-type="fig"}, removing any of the included studies had no significant influence on the overall results of these groups mentioned above.

Publication bias
----------------

We used funnel plot and Egger\'s tests to evaluate the publication bias of included studies researching on the association between *CCNE1* overexpression and OS (Figure [5](#F5){ref-type="fig"}, Egger\'s test, *p*=0.149). No evidence of significant publication bias was found. We did not analyze the publication bias of meta-analyses for the other groups mentioned above as the quantity of included studies was too small (\<10) to make a valid statistical test.

Discussion
==========

In cancer development, deregulation of cell cycle regulators was considered to be a prerequisite. *CCNE1* located on the chromosomal band 19q12, was first isolated in 1991 [@B64]. Cyclin E1 functioning as a regulatory subunit of CDK2, played significant roles in chromosomal instability and apoptosis in cancer cells [@B5]. In addition, researchers recently discovered that Cyclin E1 also had kinase-independent functions in cell-cycle progression [@B13]. Overexpression and amplification of *CCNE1* were reported to be associated with poor prognosis in a variety of cancers such as bladder cancer [@B6], ovarian cancer [@B8] and so on, while some opposite results existed [@B9], [@B10]. Even in subtypes of a single type cancer, *CCNE1* had different prognosis roles. For instance, *CCNE1* overexpression was related to a significantly increased risk of death and relapse in basal-like and triple receptor-negative breast cancers, while there was a lack of such association in hormone receptor-positive and luminal breast cancers [@B65]. So the prognostic value of *CCNE1* in cancer patients remained unclear.

*CCNE2* was located on the chromosomal band 8q22.1 [@B66]. Although Cyclin E1 and E2 were often coordinately regulated, and exhibited high homology within their important functional regions (47% between the overall sequences and 70% identity between the cyclin box) [@B67], which appeared to be functionally redundant, recently, more and more evidence suggested that Cyclin E1 and E2 were frequently expressed independently of one another in cancers, which had unique relationship with cancer prognosis. For example, it had been reported that Cyclin E2 overexpression was an independent and better prognostic signature for HER2 and luminal B breast cancer, when compared with Cyclin E1 [@B12]. Besides, both *CCNE2* overexpression and amplification were related to endocrine therapy resistance in breast cancer [@B12], [@B68]. However, in many studies, Cyclin E1 and Cyclin E2 were collectively referred to as Cyclin E, while in other articles, Cyclin E1 was called as Cyclin E. This inconsistency led us to conduct this meta-analysis for the prognosis value of Cyclin E1 in cancers rather than Cyclin E. We excluded articles about Cyclin E without definite indication of Cyclin E1 (or *CCNE1*) to avoid the possible confounding affect caused by Cyclin E2.

In this meta-analysis, a total of 20 studies were included and 5 survival assessment parameters (OS, PFS, RFS, CSS and DMFS) were measured. The results of meta-analysis indicated that *CCNE1* amplification predicted worse OS rather than PFS and RFS in cancer patients. However, it was noteworthy that the number of the included studies about *CCNE1* amplification for PFS or RFS was relatively small. And in studies adopting multivariate analysis, *CCNE1* amplification carriers showed significantly worse PFS.*CCNE1* overexpression was associated with worse OS, PFS and DMFS rather than RFS and CSS. Nevertheless, of 5 included studies for the relationship between *CCNE1* overexpression and RFS, there were 4 studies with HR and 95% CI reported directly from literatures, and *CCNE1* overexpression predicted poorer RFS in these 4 studies. Therefore, generally, *CCNE1* amplification and overexpression indicated worse prognosis of patients with cancer. Heterogeneity was found to be significant for each analysis group in this meta-analysis, except for the group researching on the correlation of *CCNE1* overexpression with PFS (I^2^=41%, *p*=0.148). So we carried out detailed subgroup analysis to examine the potential sources of heterogeneity under a broader range of study level circumstances, which showed that for different analysis groups, the causes of heterogeneity were diversified. Contrary to the pooled result of all the involving cancers in each analysis group, in ovarian cancer patients,*CCNE1* amplification had no prognosis value on OS, and *CCNE1* overexpression also didn\'t predict worse OS or PFS. It was quite unexpected, as researches about ovarian cancer accounted for the largest share in the included studies of these analysis groups. However, some studies had reported that *CCNE1* amplification or overexpression could select ovarian cancer patients more likely to benefit from CDK2 targeted therapies [@B69], [@B70]. And then, because the prognostic value of *CCNE1* was reported to be affected by germline or somatic mutations of *BRCA1/2* in ovarian cancer [@B48], so we suspected that the mutation rate of *BRCA1/2* in different studies affected the assessment of the prognostic value of CCNE1 in ovarian cancer. In the future, we believed that the research for the role of CCNE1 in the prognosis of ovarian cancer needed to be carried adjusting for *BRCA1/2*. The sensitivity analysis showed that no individual study could significantly influence the conclusion in each analysis group of our research, indicating the credibility and stability of our meta-analysis results.

There were several limitations of this meta-analysis, which should be addressed. First, there were a variety of survival assessment parameters, while only 20 articles were included, therefore studies specific to some analysis groups were relatively insufficient, limited data availability for these groups reduced the credibility of our results. Second, we excluded a number of articles for Cyclin E without indication of Cyclin E1 (or *CCNE1*). Although this strategy avoided the possible confounding affect from Cyclin E2, it may inevitably delete some researches exactly about *CCNE1*. Third, despite no significant publication bias was observed in studies researching on the association between *CCNE1* overexpression and OS, publication bias may still exist. Because we did not perform publication bias analysis for the other analysis groups as the quantity of included studies in them was too little; most articles reported positive results, whereas those with negative findings generally were less likely to be published; despite we tried to collect all relevant researches, but inevitably, some studies may still be missing. Fourth, the cut-off definition for *CCNE1* overexpression was not unified among the included studies. Finally, HR and 95% CI in some studies were calculated based on the data extracted from survival curve, which may be less reliable than that reported directly in articles.

Despite the limitations described above, to our knowledge, this was the first meta-analysis about the predictive roles of *CCNE1* amplification and overexpression in the prognosis of various cancers. Our systematic review and meta-analysis suggested that, on the whole, *CCNE1* amplification and overexpression were associated with poor prognosis in cancer patients, which meant that *CCNE1* could be hopefully applied to clinical work as a prognostic signature for cancers. Additionally, *CCNE1* overexpression showed a more important role in prognosis than *CCNE1* amplification in cancer patients. Unexpectedly, both amplification and overexpression of *CCNE1* had no prognostic prediction ability in ovarian cancer patients. At last, the total number of our included studies was relatively small, more clinical investigations with larger sample size, multicenter, higher quality and prospective design were strongly needed to further validate the prognostic role of *CCNE1* in cancer patients.
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:   not reported

EC

:   endometrial carcinomas

EAC

:   esophageal adenocarcinoma

UTUC

:   upper tract urothelial carcinoma
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:   overall survival

PFS

:   progression free survival, RFS: recurrence free survival, CSS: cancer specific survival

DMFS

:   distant metastasis free survival

CDK2

:   cyclin dependent kinase 2

MeSH

:   Medical Subject Headings
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:   Hazard ratio

95% CI

:   95% confidence interval

K-M curve

:   Kaplan-Meier curve
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:   Newcastle-Ottawa Scale

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

FISH

:   fluorescence in situ hybridization

PCR

:   polymerase chain reaction

CISH

:   chromogenic in situ hybridization

IHC

:   immunochemistry

RT-qPCR

:   real-time quantitative polymerase chain reaction.
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![Forest plots of associations between *CCNE1* overexpression and survival in cancer patients. **(A)** Effect of *CCNE1* overexpression on overall survival. **(B)** Effect of *CCNE1* overexpression on progression free survival. **(C)** Effect of *CCNE1* overexpression on recurrence free survival.**(D)** Effect of *CCNE1* overexpression on cancer specific survival. **(E)** Effect of *CCNE1* overexpression on distant metastasis free survival.](jcav09p2397g003){#F3}

![Forest plots of sensitivity analysis for the included studies on *CCNE1* amplification. Pooled hazard ratios and 95% confidence intervals by omitting each study. **(A)** For overall survival group.**(B)** For progression free survival group.](jcav09p2397g004){#F4}

![Forest plots of sensitivity analysis for the included studies on *CCNE1* overexpression. Pooled hazard ratios and 95% confidence intervals by omitting each study. **(A)** For overall survival group. **(B)** For progression free survival group.**(C)** For recurrence free survival group. **(D)** For cancer specific survival group. **(E)** For distant metastasis free survival group.](jcav09p2397g005){#F5}

![Egger\'s funnel plot for publication bias among the included studies exploring prognostic values of *CCNE1* overexpression for overall survival.](jcav09p2397g006){#F6}

###### 

Characteristics of the included 6 studies that researching on the predictive value of *CCNE1* amplification for cancers prognosis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)      Inclusion\   Country           Research\     Tumor Type               Case\          Median/Range\      Detection\        Outcome\   Amplication\   Variance\      HR\         Region
                     period                         center                                 /Control       of follow-up(Mo)   method            measures   percentage     analysis       source      
  ------------------ ------------ ----------------- ------------- ------------------------ -------------- ------------------ ----------------- ---------- -------------- -------------- ----------- ---------------
  Ayhan A(2016)      1995-2013    Muti-country^a^   multicenter   ovarian cancer           13/70          NR                 FISH              OS         15.66          Univariate     Reported    Mixed

  Nakayama K(2015)   1998-2010    Japan             single        endometrial carcinomas   9/99           52(5-139)          FISH              OS PFS     8.33           Multivariate   Reported    Asia

  Pils D(2014)       2005-2008    Muti-country^b^   multicenter   ovarian cancer           total^c^ 167   49(1-69)           copy number PCR   OS PFS     25             Univariate     Reported    Europe

  TCGA(2011)         NR           USA               multicenter   ovarian cancer           106/383        30(1-179)          microarray        OS         21.68          Univariate     K-M curve   North America

  Nakayama N(2010)   NR           Japan             single        ovarian cancer           18/70          NR                 FISH              OS PFS     20.45          Multivariate   Reported    Asia

  Luhtala S(2016)    2003-2007    Finland           single        breast cancer            15/170         64.8               CISH              RFS        8.11           Univariate     Reported    Europe
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

a: Japan, USA. b: Germany, Belgium, Austria. c: total: the study didn\'t provide detail number of control and case group.

###### 

Characteristics of the included 19 studies that researching on the predictive value of *CCNE1* overexpression for cancers prognosis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)        Inclusion\   Country           Research\     Tumor\           Case/\               Median/\           Detection\   Cut-off       Outcome\   High\                   Variance\          HR\         Region
                       period                         center        Type             Control              Range\             method                     measures   expression percentage   analysis           source      
                                                                                                          of follow-up(Mo)                                                                                                
  -------------------- ------------ ----------------- ------------- ---------------- -------------------- ------------------ ------------ ------------- ---------- ----------------------- ------------------ ----------- ---------------
  Ayhan A(2016)        1995-2013    Muti-country^a^   multicenter   ovarian cancer   20/63                NR                 IHC          80%^b^        OS         24.1                    Multivariate       Reported    Mixed

  Nakayama K(2015)     1998-2010    Japan             single        EC               54/54                52(5-139)          IHC          median^c^     OS PFS     50                      Univariate         Reported    Asia

  Zhou Z(2014)         2002-2008    USA               single        EAC              total^d^ 112         39(0.3-142)        IHC          10%^e^        OS         NR                      Univariate         K-M curve   North America

  Wu S(2014)           NR           China             single        UTUC             59/44                39(1-98)           IHC          5^f^          OS         57.28                   Multivariate       Reported    Asia

  Nakayama N(2010)     NR           Japan             single        ovarian cancer   44/44                NR                 IHC          median        OS PFS     50                      Univariate         Reported    Asia

  Farley J(2003)       NR           USA               multicenter   ovarian cancer   62/77                NR                 IHC          mean^g^       OS         44.6                    Multivariate       Reported    North America

  Shariat SF(2006)     1987-2002    USA               single        bladder cancer   125/99               NR                 IHC          30%^h^        CSS RFS    55.31                   Univariate         K-M curve   North America

  Chappuis PO(2005)    1980-1995    Canada            single        breast cancer    67/186               96                 IHC          50%^i^        CSS        26.48                   Univariate         K-M curve   North America

  Lotan Y(2013)        2002-2012    USA               single        bladder cancer   183/216              NR                 IHC          30%^j^        CSS RFS    84.72                   Univariate         Reported    North America

  Lundgren C(2015)     1993-2004    Sweden            multicenter   breast cancer    186/186              NR                 IHC          NR            CSS DMFS   48.45                   Univariate         Reported    Europe

  Luhtala S(2016)      2003-2007    Finland           single        breast cancer    74/128               64.8               IHC          50%^k^        RFS        36.63                   Univariate         Reported    Europe

  Matsushita R(2015)   2003-2013    Japan             single        bladder cancer   30/30                NR                 RT-qPCR      median        OS         50                      Univariate         K-M curve   Asia

  Pils D(2014)         2005-2008    Muti-country^l^   multicenter   ovarian cancer   total^d^ 167         49(1-69)           RT-qPCR      none          OS PFS     none                    OS:Multivariate\   Reported    Europe
                                                                                                                                                                                           PFS:Univariate                 

  Marchini S(2008)     1992-2003    Italy             single        ovarian cancer   OS:9/59; PFS:10/57   NR                 RT-qPCR      OS(0.124);\   OS PFS     OS:13.23\               Multivariate       Reported    Europe
                                                                                                                                          PFS(0.34)                PFS:14.93                                              

  Sieuwerts AM(2006)   1979-1995    Netherland        multicenter   breast cancer    317/318              95(11-202)         RT-qPCR      median        OS DMFS    49.92                   Multivariate       Reported    Europe

  Jansen MP(2011)      1981-1996    Netherland        single        breast cancer    total^d^ 226         89(10-165)         RT-qPCR      none          PFS        none                    Multivariate       Reported    Europe

  Kreike B(2010)       1984-1995    Netherland        single        breast cancer    total^d^ 291         80.4(0.6-237.9)    microarray   none          RFS        none                    Univariate         Reported    Europe

  Desmedt C(2006)      NR           UK                single        breast cancer    total^d^ 205         97.32              RT-qPCR      median        RFS        50                      Univariate         Reported    Europe

  Fredholm H(2017)     1992-2005    Swedish           multicenter   breast cancer    435/422              115.2              IHC          10%^m^        DMFS       50.76                   Univariate         Reported    Europe
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

a: Japan, USA. b: diffuse and intense immunoreactivity in 80% of tumor cells were considered highly expressed. c: median value. d: total: the study didn\'t provide detail number of control and case group. e: 10% or more of cells stained with a moderate to strong intensity was considered highly expressed. f: staining index score = 5. g: mean value. h: CCNE1 immunoreactivity was considered high when samples demonstrated more than 30% nuclear reactivity. i: CCNE1 immunoreactivity was considered high when samples demonstrated more than 50% nuclear reactivity. j: CCNE1 immunoreactivity was considered high when samples demonstrated more than 30% nuclear reactivity. k: CCNE1 immunoreactivity was considered high when samples demonstrated more than 50% nuclear reactivity. l: Germany, Belgium, Austria. m: CCNE1 immunoreactivity was considered high when samples demonstrated more than 10% nuclear reactivity.
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